Insulin degludec as an ultralong-acting basal insulin once a day: A systematic review

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 191-204

  Wang, Fei ^a   Surh, Justine ^a   Kaur, Manmeet ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NEW BRITAIN GENERAL HOSPITAL   (United States)

Author keywords

Basal insulin analog analogue; Comparative study; Degludec; Degludec aspart; Efficacy; IDeg; IDegAsp; NN1250; Safety

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE;

AREA UNDER THE CURVE; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN STUDY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMACH DISCOMFORT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84868523718     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s21979     Document Type: Review

References (68)

1. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab. 2005;31(4 Pt 2):4S25-24S33.
2. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2diabetes. Diabetes Care. 2005;28(4):950-955.
3. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56-64.
4. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7(1):73-82.
5. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26(3):590-596.
6. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23(5):639-643.
7. Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 study group. Diabetes Care. 2000;23(8):1130-1136.
8. Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008;10(4):273-277.
9. Raslová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27(4):279-285.
10. Hollander P, Cooper J, Bregnhoj J, Pederson CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-1987.
11. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
12. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25(6):542-548.
13. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009;11(6):623-631.
14. Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther. 2011;13(Suppl 1):S15-S24.
15. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;7:CD006383.
16. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Paper presented at: American Diabetes Association (ADA) 71st Scientific Session; Jun 2011; San Diego, CA, USA.
17. Mathieu C, Fulcher G, Rao PV, et al. Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: Comparison to insulin glargine. Diabetologia. 2010;53(Suppl 1):S8.
18. Meneghini L, Atkin SL, Bain S, et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes. Paper presented at: American Diabetes Association (ADA) 71st Scientific Session; Jun 2011; San Diego, CA, USA.
19. Birkeland KI, Raz I, Gough S, et al. Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
20. Atkin SL, Bain SC, Gough S, et al. Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
21. Home PD, Meneghini L, Ratner RE, et al. A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
22. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes. 2010;59(Suppl 1):A11.
23. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec: Multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin. Diabetologia. 2010;53(Suppl 1):S388.
24. Meneghini LF, Miranda-Palma B. Insulin degludec: A novel ultra-long-acting basal insulin for use in type 1 and 2 diabetes. Expert Rev Endocrinol Metab. 2012;7(1):9-14.
25. Nosek L, Heise T, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. Paper presented at: American Diabetes Association (ADA) 71st Scientific Session; Jun 2011; San Diego, CA, USA.
26. Russell-Jones DL, Francisco AO, Pei H, Heller SR. Basal-bolus therapy with insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine in type 1 diabetes: Results of a 1-year trial. Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting;Sept 2011; Lisbon, Portugal.
27. Pieber T, Korsatko S, Koumlhler G, et al. Response to induced hypoglycemia in type 1 diabetes: Insulin degludec elicits an enhanced counter-regulatory hormone response compared to insulin glargine. Paper presented at: American Diabetes Association (ADA) 71st Scientific Session; June 2011; San Diego, CA.
28. Heller S, Francisco AO, Pei H, Russell-Jones D. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes. Paper presented at: American Diabetes Association 71st Scientific Sessions; Jun 2011; San Diego, CA.
29. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661-665.
30. Meneghini LF, Home PD, Wendisch U, et al. Insulin degludec, a new generation ultra-long acting insulin, in a mealtime + basal regimen in people with type 1 diabetes: Comparison to insulin glargine. Diabetologia. 2010;53(Suppl 1):S381.
31. Cuddihy R, Tack CJ, Heise T, et al. Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive people with type 2 diabetes: Comparison with insulin glargine. Diabetologia. 2010;53(Suppl 1):S389.
32. Hollander PA, King AB, Francisco AO, Endahl L, Garber A. Basal-bolus therapy with insulin degludec improves long-term glycaemic control with fewer nocturnal hypoglycaemic events compared with insulin glargine in people with type 2 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
33. Garber AJ, King AB, Francisco AO, Endahl L, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes. Paper presented at: American Diabetes Association (ADA) 71st Scientific Sessions; Jun 2011; San Diego, CA.
34. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924-931.
35. Heise T, Hermanski L, Nosek I, et al. Insulin degludec: Less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53(Suppl 1):S387.
36. Hirsch I, Franek E, Courrèges JP, Mersebach H, Dykiel P, Bode BW. IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
37. Hirsch IB, Franek E, Courreges J, Mersebach H, Dykiel P, Bode BW. Efficacy and safety of a new basal insulin with a bolus boost (IDegAsp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes. Paper presented at: American Diabetes Association 71st Scientific Sessions; Jun 2011; San Diego, CA.
38. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669-674.
39. Heller SR, Pieber TR, Korsatko S, et al. A higher counter-regulatory hormone response is seen with insulin degludec than insulin glargine in response to induced hypoglycaemia in type 1 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
40. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation. J Pept Sci. 2010;16(Suppl 1):32.
41. Vaag A, Leiter LA, Franek E, et al. Use of a new basal insulin with a bolus boost (IDegAsp) in type 2 diabetes: Comparison with biphasic insulin aspart 30 (BIAsp 30). Paper presented at: American Diabetes Association (ADA) 71st Scientific Session; Jun 2011; San Diego, CA.
42. Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: Bio-equivalence and similar pharmacodynamics shown for two different formulations (U100 and U200). Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
43. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Paper presented at: American Diabetes Association 71st Scientific Sessions; Jun 2011; San Diego, CA.
44. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H. The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. Paper presented at: American Diabetes Association 71st Scientific Sessions; June 2011; San Diego, CA.
45. Danne T, Biester T, Blaesig S, et al. The pharmacokinetic properties of insulin degludec in children and adolescents compared with adults with type 1 diabetes after single-dose administration. Pediatric Diabetes. 2011;12(Suppl 15):35-36.
46. ClinicalTrials.gov. Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects. [updated 2011 November 28]. Available at: http://clinicaltrials.gov/show/NCT01437592. Accessed December 30, 2011.
47. Meneghini LF, Home PD, Wendisch U, et al. Insulin degludec, a new generation ultra-long acting insulin, in a mealtime plus basal regimen in people with type 1 diabetes: Comparison to insulin glargine. Diabetes. 2010;59(Suppl 1):A152.
48. Home PD, Meneghini L, Wendisch U, et al. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabet Med. 2011. doi:10.1111/j.1464-5491.2011.03547.x.
49. Vaag LA, Leiter E, Franek J, et al. IDegAsp, a soluble insulin combination of ultra-long acting insulin degludec and insulin aspart, in type 2 diabetes: Comparison with biphasic insulin aspart 30. Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.
50. Bain S, Atkin S, Gough S, et al. Flexible once-daily dosing of insulin degludec is as efficacious and safe as insulin glargine given the same time each day in type 2 diabetes. Paper presented at: World Diabetes Congress (International Diabetes Federation); Dec 2011, Dubai.
51. Niskanen L, Leiter LA, Franek E, et al. IDegAsp, a soluble insulin combination of insulin degludec and insulin aspart, in type 2 diabetes: Comparison to biphasic insulin aspart 30. Paper presented at: World Diabetes Congress (International Diabetes Federation); Dec 2011, Dubai.
52. Clinical Trials at Novo Nordisk [homepage on the Internet]. Available at: HYPERLINK http://www.novonordisk-trials.com/t_blank www.novonordisk-trials.com. Accessed January 14, 2012
53. Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol. 2010;47(4):271-278.
54. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41-49.
55. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999-1005.
56. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507-2512.
57. Kellerer M, Häring H. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clinl Endocrinol Diabetes. 2001;109(1):63-64.
58. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003;25(6):1541-1577; discussion 1539-1540.
59. Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res. 2011;43(1):1-10.
60. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732-1744.
61. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52(9):1755-1765.
62. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745-1754.
63. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33(9):1997-2003.
64. US Food and Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. [updated 2011 January 20]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm. Accessed March 17, 2012.
65. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011;13(Suppl 1):S103-S108.
66. Nishimura E, Sorensen AR, Hansen BF, et al. Insulin degludec: A new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia. 2010;53 (Suppl 1):S388.
67. Nishimura E, Sorensen A, Hansen BF, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetes. 2010;59(Suppl 1):A375.
68. Ahrén B, Burke B. Using albumin to improve the therapeutic properties of diabetes treatments. Diabetes Obes Metab. 2012;14(2):121-129.